Medirx Digital Therapeutics
Transforming Global Healthcare by Advancing Digital Therapeutics
Digital therapeutics (DTx) are changing the healthcare delivery system with evidence-based technologies that improve patient outcomes.
Understanding DTx
A New Category of Medicine Digital therapeutics (DTx) deliver medical interventions directly to patients using evidence-based, clinically evaluated software to treat, manage, and prevent a broad spectrum of diseases and disorders.
A New Category of Medicine Digital therapeutics (DTx) deliver medical interventions directly to patients using evidence-based, clinically evaluated software to treat, manage, and prevent a broad spectrum of diseases and disorders.
Foundational Documents
DTx products are held to the same standards of evidence and regulatory oversight as traditional medical treatments. Digital therapeutics must adhere to all ten core principles to demonstrate product safety, efficacy, quality, patient centricity, privacy, and ongoing clinical impact. Addressing Challenges in Global Healthcare Digital therapeutics are essential to healthcare delivery systems. They eliminate gaps in care by: Delivering therapies using smartphones, tablets, and similar technologies Increasing patient access to clinically safe and effective therapies Lowering stigma associated with the delivery of certain traditional therapies by offering at-home convenience and privacy Extending clinicians’ ability to care for patients Providing therapies in various languages, such as English, Spanish, Arabic, German, and French Providing meaningful results and insights on personalized goals and outcomes to patients and their clinicians DTx products can address critical gaps in care for underserved populations, regardless of patient age, language, culture, income, disease state, or geography. Read DTA’s report on the value of digital therapeutics for rural and underserved populations.
DTx products are held to the same standards of evidence and regulatory oversight as traditional medical treatments. Digital therapeutics must adhere to all ten core principles to demonstrate product safety, efficacy, quality, patient centricity, privacy, and ongoing clinical impact. Addressing Challenges in Global Healthcare Digital therapeutics are essential to healthcare delivery systems. They eliminate gaps in care by: Delivering therapies using smartphones, tablets, and similar technologies Increasing patient access to clinically safe and effective therapies Lowering stigma associated with the delivery of certain traditional therapies by offering at-home convenience and privacy Extending clinicians’ ability to care for patients Providing therapies in various languages, such as English, Spanish, Arabic, German, and French Providing meaningful results and insights on personalized goals and outcomes to patients and their clinicians DTx products can address critical gaps in care for underserved populations, regardless of patient age, language, culture, income, disease state, or geography. Read DTA’s report on the value of digital therapeutics for rural and underserved populations.
Value of DTx / Patients & Caregivers
New Effective Therapy Options Digital therapeutics are clinically proven to treat, manage, and prevent a wide range of diseases and disorders using software-based technologies. DTx products deliver medical interventions directly to patients or integrate with other digital health technologies, medications, or in-person therapies to: Improve patient health Deliver a highly engaging and user-friendly experience Provide meaningful results and insights on personalized goals and outcomes Easily scale and be accessible via smartphones and tablets Ensure patient safety and privacy protection
New Effective Therapy Options Digital therapeutics are clinically proven to treat, manage, and prevent a wide range of diseases and disorders using software-based technologies. DTx products deliver medical interventions directly to patients or integrate with other digital health technologies, medications, or in-person therapies to: Improve patient health Deliver a highly engaging and user-friendly experience Provide meaningful results and insights on personalized goals and outcomes Easily scale and be accessible via smartphones and tablets Ensure patient safety and privacy protection
Value of DTx / Clinicians
Trustworthy and Effective Therapy Options DTx products represent a new category of evidenced-based therapeutic technologies that support clinicians in the delivery of high-quality patient care. They address a range of disease states and provide a wide variety of software-based interventions. DTx products are used independently or in concert with other medical therapies to: Directly impact disease state measures and clinical outcomes Expand access to safe, confidential, and effective medical treatments Provide therapies for previously un- or undertreated conditions Extend clinicians’ ability to care for patients Maximize patient engagement Close gaps in care Lower overall healthcare costs Because of their easy accessibility, record of improving outcomes, ability to integrate into care management workflows, delivery of real-world insights, and increased reimbursement by payors, DTx products are becoming critically important tools for clinicians and their care teams.
Trustworthy and Effective Therapy Options DTx products represent a new category of evidenced-based therapeutic technologies that support clinicians in the delivery of high-quality patient care. They address a range of disease states and provide a wide variety of software-based interventions. DTx products are used independently or in concert with other medical therapies to: Directly impact disease state measures and clinical outcomes Expand access to safe, confidential, and effective medical treatments Provide therapies for previously un- or undertreated conditions Extend clinicians’ ability to care for patients Maximize patient engagement Close gaps in care Lower overall healthcare costs Because of their easy accessibility, record of improving outcomes, ability to integrate into care management workflows, delivery of real-world insights, and increased reimbursement by payors, DTx products are becoming critically important tools for clinicians and their care teams.
Value of DTx / Payors
Clinical and Financial Value The Covid-19 pandemic has exposed the challenges payors face in delivering accessible high-quality care outside of traditional office-based visits. Payors are now considering additional options for how to best meet patient needs and close gaps in care with non-traditional approaches. By combining technology and evidenced-based medicine, DTx products offer patients access to therapies that address a wide range of conditions, enabling payors to: Reduce the overall cost of care Enhance, support, and optimize current medical treatments Optimize patient engagement Improve provider network efficiency Support value- and outcomes-based care initiatives Expand care delivery outside of traditional clinic settings Improve member experience and satisfaction Insights and information collected by digital technologies are easily integrated within care management workflows to provide payors with valuable insights that support population health management and value-based care initiatives.
Clinical and Financial Value The Covid-19 pandemic has exposed the challenges payors face in delivering accessible high-quality care outside of traditional office-based visits. Payors are now considering additional options for how to best meet patient needs and close gaps in care with non-traditional approaches. By combining technology and evidenced-based medicine, DTx products offer patients access to therapies that address a wide range of conditions, enabling payors to: Reduce the overall cost of care Enhance, support, and optimize current medical treatments Optimize patient engagement Improve provider network efficiency Support value- and outcomes-based care initiatives Expand care delivery outside of traditional clinic settings Improve member experience and satisfaction Insights and information collected by digital technologies are easily integrated within care management workflows to provide payors with valuable insights that support population health management and value-based care initiatives.
Value of DTx
Changing the Face of Healthcare Worldwide Digital therapeutics are expanding what is globally achievable in healthcare through advanced technologies that offer increased therapy accessibility and personalization. By definition, DTx products deliver therapeutic interventions directly to patients using evidence-based, clinically evaluated software to treat, manage, and prevent a broad spectrum of diseases and disorders.
Changing the Face of Healthcare Worldwide Digital therapeutics are expanding what is globally achievable in healthcare through advanced technologies that offer increased therapy accessibility and personalization. By definition, DTx products deliver therapeutic interventions directly to patients using evidence-based, clinically evaluated software to treat, manage, and prevent a broad spectrum of diseases and disorders.
The Value of DTx Products
DTx products, using evidence-based, clinically evaluated technologies, have the ability to: Optimize clinical and health economic outcomes Deliver high quality therapies to underserved populations Easily scale and be accessible through patient-owned devices Offer at-home convenience and privacy Transform how patients understand, manage, and engage in their healthcare Extend clinicians’ ability to care for patients Support healthcare teams in settings with varying degrees of health care infrastructure Lower overall costs of care
DTx products, using evidence-based, clinically evaluated technologies, have the ability to: Optimize clinical and health economic outcomes Deliver high quality therapies to underserved populations Easily scale and be accessible through patient-owned devices Offer at-home convenience and privacy Transform how patients understand, manage, and engage in their healthcare Extend clinicians’ ability to care for patients Support healthcare teams in settings with varying degrees of health care infrastructure Lower overall costs of care
Advancing DTx
Improving Clinical and Health Economic Outcomes As the leading international organization on digital therapeutic thought leadership and education, DTA is dedicated to providing patient, clinicians, payors, and policymakers with the necessary tools to evaluate and utilize DTx products. DTA’s members – including organizations dedicated to manufacturing, evaluating, supporting, and utilizing DTx products in clinical practice – work to enable expanded access to DTx products to improve clinical and health economic outcomes. Current Initiatives DTA is proud to advance digital therapeutics globally by: Establishing the formal definition of a digital therapeutic and core principles to which all DTx products must adhere Enabling clinicians and decision makers to adopt and integrate DTx products into healthcare to improve patient and population clinical and economic outcomes Assisting policymakers as they work to recognize digital therapeutics within national and regional regulatory frameworks Educating end users about DTx products and their short- and long-term value Collaborating with DTA member companies and ecosystem stakeholders to optimize industry impact DTA’s report “Digital Therapeutics: Reducing Rural Health Inequalities,” calls for Medicare and Medicaid to leverage evidence-based digital therapeutics (DTx) to address critical gaps in care for underserved populations, regardless of whether disparities are based on patient age, language, culture, income, disease state, or geography. Payor Efforts DTx Product Value Assessment Guide: DTA is working to develop a framework for healthcare decision makers enabling them to better understand, evaluate, and implement digital therapeutics. More details will be provided in Summer 2021.
Improving Clinical and Health Economic Outcomes As the leading international organization on digital therapeutic thought leadership and education, DTA is dedicated to providing patient, clinicians, payors, and policymakers with the necessary tools to evaluate and utilize DTx products. DTA’s members – including organizations dedicated to manufacturing, evaluating, supporting, and utilizing DTx products in clinical practice – work to enable expanded access to DTx products to improve clinical and health economic outcomes. Current Initiatives DTA is proud to advance digital therapeutics globally by: Establishing the formal definition of a digital therapeutic and core principles to which all DTx products must adhere Enabling clinicians and decision makers to adopt and integrate DTx products into healthcare to improve patient and population clinical and economic outcomes Assisting policymakers as they work to recognize digital therapeutics within national and regional regulatory frameworks Educating end users about DTx products and their short- and long-term value Collaborating with DTA member companies and ecosystem stakeholders to optimize industry impact DTA’s report “Digital Therapeutics: Reducing Rural Health Inequalities,” calls for Medicare and Medicaid to leverage evidence-based digital therapeutics (DTx) to address critical gaps in care for underserved populations, regardless of whether disparities are based on patient age, language, culture, income, disease state, or geography. Payor Efforts DTx Product Value Assessment Guide: DTA is working to develop a framework for healthcare decision makers enabling them to better understand, evaluate, and implement digital therapeutics. More details will be provided in Summer 2021.
